These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 27395059

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
    Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, Lanske B.
    Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
    [Abstract] [Full Text] [Related]

  • 3. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
    Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.
    Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
    [Abstract] [Full Text] [Related]

  • 4. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
    Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G.
    Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
    Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B.
    Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
    [Abstract] [Full Text] [Related]

  • 7. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
    Iwaniec UT, Mosekilde L, Mitova-Caneva NG, Thomsen JS, Wronski TJ.
    Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ.
    Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
    [Abstract] [Full Text] [Related]

  • 11. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY.
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats.
    Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y.
    Calcif Tissue Int; 2017 Jul; 101(1):65-74. PubMed ID: 28246925
    [Abstract] [Full Text] [Related]

  • 16. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, Clarke SL, Cullen DM, Lucas EA.
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [Abstract] [Full Text] [Related]

  • 17. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
    Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE.
    J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone increases vertebral and femoral bone strength in osteopenic, ovariectomized, aged rats in a dose-dependent and site-specific manner.
    Mosekilde L, Thomsen JS, Orhii PB, Kalu DN.
    Bone; 1998 Oct; 23(4):343-52. PubMed ID: 9763146
    [Abstract] [Full Text] [Related]

  • 19. Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats.
    Thomsen JS, Mosekilde LI, Gasser JA.
    Bone; 1999 Nov; 25(5):561-9. PubMed ID: 10574576
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.